Overview

A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis

Status:
Not yet recruiting

Trial end date:
2027-07-21

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to learn if dupilumab helps more than the placebo after 24 weeks (Part A) and if dupilumab at different doses helps more than the placebo after 24 weeks (Part B). The secondary purpose of this study is - to learn if dupilumab helps after 24 and 52 weeks (Part A, Part B and Part C) - to learn if dupilumab is safe and well tolerated and if it causes an immune response (immunogenicity) - to learn how dupilumab moves throughout the body (pharmacokinetics) - to learn how dupilumab changes the patterns of certain genetic material related to eosinophilic gastritis (EoG) and type 2 inflammation (transcriptome signatures)

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Regeneron Pharmaceuticals

Collaborator:

Sanofi

Treatments:

Antibodies, Monoclonal